This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Hypothesis Once daily lopinavir/ritonavir (LPV/r) liquid will be better tolerated than once daily LPV/r capsules.Primary Objectives To compare the tolerability of once daily LPV/r (800/200 mg) as 10 ml liquid vs. 6 capsulesSecondary Objectives1 To compare at week 4, or at the time therapy is discontinued, for each of the two 4 week Steps of the cross-over trial (Steps 1 and 2). 1.1 Maximum severity of diarrhea 1.2 Maximum severity of nausea 1.3 Use of antimotility or antiemetic therapy 1.4 Development of adverse events (AEs) other than nausea and diarrhea 1.5 Development of laboratory abnormalities, e.g. lipids, transaminases 1.6 Development of treatment-limiting toxicity 1.7 Plasma HIV-1 RNA suppression to 50 copies/mL 1.8 Level of symptoms distress2 To compare the pharmacokinetics of once daily liquid and capsules of LPV/r at week 2 of Steps 1 and 23 To determine the proportion of subjects who choose each of the therapeutic options at start of Step 34 The stated preference for liquid or capsules, and the degree of like or dislike of each in those who choose an option other than once daily LPV/r at start of Step 35 To determine the proportion of screened individuals who choose not to be randomized after the liquid LPV/r taste test at the time of enrollment into the study6 The determine rates of plasma HIV-1 RNA 50 copies/mL at the end of Step 3
Showing the most recent 10 out of 1825 publications
